Search Results

Press Releases

BioXcel Therapeutics to Present at ThinkEquity Conference

October 29, 2024

·

5 min read

Press Releases

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

November 22, 2024

·

5 min read

Press Releases

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

November 15, 2024

·

14 min read

Pharm Country

BioXcel Therapeutics to Present at Jefferies 2024 Global Healthcare Conference

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, announced that CEO Vimal Mehta, Ph.D., will present at the Jefferies Global Healthcare Conference in New York City.

May 28, 2024

·

9 min read

Press Releases

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

November 8, 2024

·

3 min read

Business

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, announced its financial results for the first quarter of 2024.

May 9, 2024

·

16 min read

Pharm Country

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

BioXcel Therapeutics, Inc. announced that Rob Risinger, M.D., Chief Medical Officer of Neuroscience, will deliver oral and poster presentations at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.

May 21, 2024

·

9 min read

Business

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

BioXcel Therapeutics, Inc. today announced that it will release its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets.

April 25, 2024

·

4 min read

Business

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

BioXcel Therapeutics, Inc. provided an update on its late-stage TRANQUILITY and SERENITY clinical programs.

March 12, 2024

·

18 min read

Pharm Country

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics, Inc. today announced positive topline results from a post-marketing requirement (PMR) study of IGALMI™ (dexmedetomidine) sublingual film that demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with the 180 mcg dose after seven days of PRN (as-needed) treatment.

June 25, 2024

·

11 min read